Zepbound is used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m^2 or greater (obesity) or 27 kg/m^2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease)
Time-to-onset analysis of NAEs associated with GLP-1 RAs The median time-to-onset of NAEs for all GLP-1 RAs was 31 days (interquartile range [IQR] 7123), with 46.25% occurring within the first 30 days of treatment initiation (Table S6, Figure S2)
Not for human or veterinary use, and not intended for injection, ingestion, topical application, or cosmetic use
This milestone paved the way for future pharmaceutical advancements and established methylene blue as a cornerstone in the development of synthetic medications